Legend Biotech Corporation
LEGN
$34.86
$1.374.09%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 55.67% | 64.01% | 77.97% | 78.28% | 115.60% |
| Total Other Revenue | 97.22% | -- | -197.50% | -197.37% | -193.83% |
| Total Revenue | 56.37% | 64.00% | 74.74% | 74.75% | 112.46% |
| Cost of Revenue | 36.89% | 26.95% | 27.70% | 17.20% | 18.51% |
| Gross Profit | 263.14% | 1,090.54% | 251.27% | 169.89% | 128.66% |
| SG&A Expenses | 19.50% | 20.18% | 22.81% | 35.48% | 38.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 320.00% | -- | -- | -- | -- |
| Total Operating Expenses | 31.78% | 25.10% | 26.33% | 22.46% | 24.24% |
| Operating Income | 43.19% | 54.89% | 45.35% | 41.39% | 45.17% |
| Income Before Tax | -19.78% | -78.79% | 35.58% | -6.02% | 57.79% |
| Income Tax Expenses | -34.22% | -24.79% | 544.91% | 1,126.38% | 1,141.52% |
| Earnings from Continuing Operations | -14.65% | -67.73% | 31.13% | -14.17% | 53.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.65% | -67.73% | 31.13% | -14.17% | 53.17% |
| EBIT | 43.19% | 54.89% | 45.35% | 41.39% | 45.17% |
| EBITDA | 44.97% | 56.40% | 46.38% | 41.77% | 45.90% |
| EPS Basic | -14.00% | -66.50% | 31.77% | -12.99% | 54.31% |
| Normalized Basic EPS | -22.33% | -82.57% | 37.53% | -3.26% | 59.77% |
| EPS Diluted | -16.10% | -68.38% | 31.56% | -12.89% | 54.38% |
| Normalized Diluted EPS | -19.83% | -77.95% | 36.38% | -4.65% | 58.93% |
| Average Basic Shares Outstanding | 0.77% | 0.83% | 0.84% | 0.90% | 1.71% |
| Average Diluted Shares Outstanding | -1.66% | -1.61% | 3.32% | 3.38% | 4.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |